AG0302-COVID‑19
Vaccine candidate against COVID-19
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | DNA |
Clinical data | |
Routes of administration | Intramuscular, Intradermal[1] |
AG0302-COVID-19 is a COVID-19 vaccine candidate developed by AnGes Inc.[2][3] This candidate followed a previous one called AG0301-COVID-19.[4]
References
- ^ "Phase I/II Study of COVID-19 DNA Vaccine (AG0302-COVID19 High-dose)". clinicaltrials.gov. United States National Library of Medicine. Archived from the original on 9 August 2021. Retrieved 6 October 2021.
- ^ "Study of COVID-19 DNA Vaccine (AG0302-COVID19)". clinicaltrials.gov. United States National Library of Medicine. 3 December 2020. Retrieved 11 March 2021.
- ^ "Phase II / III Study of COVID-19 DNA Vaccine (AG0302-COVID19)". clinicaltrials.gov. United States National Library of Medicine. Archived from the original on 8 December 2020. Retrieved 11 March 2021.
- ^ "Study of COVID-19 DNA Vaccine (AG0301-COVID19)". ClinicalTrials.gov. United States National Library of Medicine. 9 July 2020. NCT04463472. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
Scholia has a profile for AG0302-COVID‑19 (Q106514993).
Development | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Classes | |||||||||||
Administration | |||||||||||
Vaccines |
| ||||||||||
Inventors/ researchers | |||||||||||
Controversy | |||||||||||
Related | |||||||||||
|
Retrieved from "https://en.wikipedia.org/w/index.php?title=AG0302-COVID‑19&oldid=1219845089"